- Ph.D., Medicine, The University of Sheffield, U.K.
- B.Sc., Molecular Biology, Queen Mary University of London
- U.S. Patent and Trademark Office
Anna Sargsyan, Ph.D.
Anna Sargsyan, Ph.D., serves as a Patent Agent in the areas of biotechnology and pharmaceuticals.Dr. Sargsyan drafts patent applications, prosecutes U.S. patent applications (drafts responses, amendments, and appeal and reply briefs), and corresponds with foreign associates to guide the prosecution of foreign applications.
Dr. Sargsyan graduated from Queen Mary University of London (QMUL), U.K., with a B.Sc. degree in Molecular Biology in 2003 and obtained her D.Phil. (Ph.D.) in Medicine at the University of Sheffield, U.K., in 2007. Her graduate research focused on the role of brain glial cells in the pathogenesis of amyotrophic lateral sclerosis, also known as Lou Gehrig’s Disease. Dr. Sargsyan completed two postdoctoral training positions at the University of Colorado Denver (UC Denver). Her first position was in the laboratory of Dr. Don Gilden, where she studied potential antigens that trigger cellular immune responses in multiple sclerosis. She then completed her second position in the laboratory of Dr. Joshua Thurman, where she examined the applicability of iron oxide nanoparticles in non-invasive detection of inflammation. Following her research at UC Denver, Dr. Sargsyan worked at Emory University as a postdoctoral fellow in the laboratory of Prof. P. Michael Iuvone. Here, she studied the localization and potential modulatory role of a neuropeptide in the retina.
Dr. Sargsyan has professional experience in a diverse range of research disciplines, but especially in the area of neuroimmunology. She has presented her research at numerous international conferences and has co-authored several manuscripts, including “Detection of glomerular complement C3 fragments by magnetic resonance imaging in murine lupus nephritis.”, Kidney International (2012); “Molecular imaging of autoimmune diseases and inflammation.”, Molecular Imaging (2012); “A comparison of in vitro properties of resting SOD1 transgenic microglia reveals evidence of reduced neuroprotective function.”, BMC Neuroscience (2011); “Contrasting effects of cerebrospinal fluid from motor neuron disease patients on survival of primary motor neurons cultured with or without glia.”, Amyotrophic Lateral Sclerosis (2011); “Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis.”, Neurology (2010); “Mutant SOD1 G93A microglia have an inflammatory phenotype and elevated production of MCP-1.”, Neuroreport (2009); “Astrocyte function and role in motor neuron disease: a future therapeutic target?”, Glia (2009); “Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis.”, Glia (2005).